<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053189_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134628</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012MX113373</safetyreportid>
		<primarysourcecountry>MX</primarysourcecountry>
		<occurcountry>MX</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121210</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121206</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121206</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012MX113373</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>MX</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>VGML</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19360526</patientbirthdate>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Shoulder operation</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20121120</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
				<patientmedicalcomment>was discharged on 20 Nov 2012</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tendon operation</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20121120</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1992</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes mellitus</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1992</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Shoulder arthrosis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Osteoarthritis shoulders</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Osteoarthritis</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201206</reactionstartdate>
				<reactionenddateformat>610</reactionenddateformat>
				<reactionenddate>201211</reactionenddate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pain in her shoulder</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Shoulder pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Musculoskeletal pain</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201206</reactionstartdate>
				<reactionfirsttime>1</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DIOVAN</medicinalproduct>
				<obtaindrugcountry>MX</obtaindrugcountry>
				<drugbatchnumb>Unk</drugbatchnumb>
				<drugauthorizationnumb>21-283</drugauthorizationnumb>
				<drugauthorizationcountry>MX</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>320</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>320 mg, daily</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>VALSARTAN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Musculoskeletal pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Musculoskeletal pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteoarthritis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteoarthritis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>BI-EUGLUCON M</medicinalproduct>
				<obtaindrugcountry>MX</obtaindrugcountry>
				<drugbatchnumb>Unk</drugbatchnumb>
				<drugauthorizationcountry>MX</drugauthorizationcountry>
				<drugstructuredosagenumb>3</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugdosagetext>3 DF, daily</drugdosagetext>
				<drugadministrationroute>065</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blood glucose abnormal</drugindication>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>1992</drugstartdate>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>GLIBENCLAMIDE, METFORMIN HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LYRICA</medicinalproduct>
				<obtaindrugcountry>MX</obtaindrugcountry>
				<drugbatchnumb>Unk</drugbatchnumb>
				<drugauthorizationcountry>MX</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugdosagetext>1DF,daily</drugdosagetext>
				<drugadministrationroute>065</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Diabetic neuropathy</drugindication>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>PREGABALIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012MX113373, is an initial spontaneous report from a consumer (patient) received on 06 Dec 2012. This report refers to a 76-year-old female patient. The patient's medical history included hypertension diagnosed 20 years ago and diabetes diagnosed 20 years ago. Concomitant medications included Bi-Euglucon M (glibenclamide/metformin hydrochloride) and Lyrica (pregabalin). The patient received Diovan (valsartan) for the treatment of hypertension, from an unspecified date at a dose of 320mg, daily. Patient reported that in Jun 2012 (date unspecified) she started with pain in her shoulder therefore she visited her physician who diagnosed &#8220;shoulder arthrosis&#8221; (no treatment was given to her at that moment). Patient further informed that on 20 Nov 2012, she underwent &#8220;shoulder surgery&#8221; and &#8220;reconstruction of some tendons (unspecified).&#8221; Patient had started the treatment with Tafirol (ketoprofen) and Dolac (ketorolac tromethamine) both for &#8220;pain control.&#8221; Treatment with Diovan was reported as ongoing. The outcome of the events was reported as completely recovered. Causality and seriousness of the events were not reported.</narrativeincludeclinical>
				<sendercomment>Confounders include patient&#8217;s age. However, without information on the start date of suspect drug, a proper causality assessment cannot be performed. Case will be reassessed on receipt of follow-up information.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
